Brain tumor research and treatment最新文献

{"title":"Spontaneous Cranial Epidural Inflammatory Granuloma Mimicking Brain Tumor: A Case Report.","authors":"Ho-Shin Gwak, June Young Chun, Na Young Han, So Hyeon Ji, Soyoung Choi, Young Joo Choi","doi":"10.14791/btrt.2025.0027","DOIUrl":"10.14791/btrt.2025.0027","url":null,"abstract":"<p><p>Here, we report a case of spontaneous cranial epidural inflammatory granuloma occurring in an 87-year-old female patient. The patient had a longstanding history of diabetes, which was managed with insulin. She developed reading and speech difficulties 1 month prior to presentation, and on the day of her visit to the ER, she had a partial seizure. Non-contrast CT results showed an ill-defined iso- to mild hyperdense lesion on the left frontal lobe with severe perilesional edema, giving the impression of a brain tumor. Subsequent MRI results showed an irregular, rim-enhancing lesion involving the brain parenchyma and epidural space without diffusion restriction, suggestive of an infectious granuloma. An initial workup was performed, including various cultures and chest CT to rule out possible infectious sources, but all results were negative. Thus, an excisional biopsy was performed, and intraoperative findings revealed an epidural granulomatous lesion invading the dura and extending to the pial surface. Intraoperative tissue 16s rRNA polymerase chain reaction (PCR) was positive for <i>Staphylococcus aureus</i>, and tissue cultures later confirmed the strain to be methicillin-resistant <i>S. aureus</i>. After the PCR, the patient was additionally given vancomycin. She improved completely, regaining her previous average daily living function.</p>","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":"13 4","pages":"158-163"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12621856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145496816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative Seizures Can Predict Overall Survival of Patients With Newly Diagnosed Supratentorial Isocitrate Dehydrogenase-Wild Glioblastoma Treated With Radiotherapy Plus Concomitant and Adjuvant Temozolomide.","authors":"Kengo Yamada, Ryosuke Matsuda, Ryota Sasaki, Ryosuke Maeoka, Tsutomu Nakazawa, Takayuki Morimoto, Yudai Morisaki, Shohei Yokoyama, Masashi Kotsugi, Yasuhiro Takeshima, Shuichi Yamada, Fumihiko Nishimura, Young-Soo Park, Ichiro Nakagawa","doi":"10.14791/btrt.2025.0022","DOIUrl":"10.14791/btrt.2025.0022","url":null,"abstract":"<p><strong>Background: </strong>We aimed to evaluate the correlation between postoperative seizures (POS) and overall survival in patients with newly diagnosed supratentorial isocitrate dehydrogenase (IDH)-wild glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.</p><p><strong>Methods: </strong>This study included 122 patients with newly diagnosed supratentorial IDH-wild glioblastoma who were treated at our hospital between May 2007 and September 2022. Seizures occurring within 7 days after surgery were defined as immediate POS (iPOS). Moreover, seizures from the 8th day after the surgery were defined as delayed POS (dPOS).</p><p><strong>Results: </strong>The median follow-up period and median survival time (MST) from surgery in the entire cohort were 19.3 and 20.4 months, respectively. The rates of iPOS and dPOS in this study were 6.6% (n=8) and 38.5% (n=47), respectively. The MST of patients with iPOS and without iPOS was 27.6 and 20 months, respectively. There was no significant difference between with iPOS and without iPOS. The median time to onset of dPOS was 126 days after surgery. The MST of patients with dPOS and without dPOS was 25.9 and 18.4 months, respectively. Patients with dPOS showed significantly longer survival than those without dPOS (<i>p</i>=0.024). Occurrence of seizures at the initial manifestation of disease was found to be significantly more likely to cause dPOS (<i>p</i>=0.044).</p><p><strong>Conclusion: </strong>Among patients with newly diagnosed supratentorial IDH-wild glioblastoma, the prognosis of patients with seizures in the postoperative course was better than that of patients without dPOS.</p>","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":"13 4","pages":"140-146"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12621835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145497600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction of Content, Table, and Funding Statement of the Article \"Intraoperative Language Area Mapping: Cortico-Cortical Evoked Potential\".","authors":"Tae-Min Cheon, Soo-Hyun Yoon, Myoung-Jeong Kim, Kyung-Min Kim","doi":"10.14791/btrt.2025.0008e","DOIUrl":"10.14791/btrt.2025.0008e","url":null,"abstract":"<p><p>This corrects the article on p. 39 in vol. 13, PMID: 40347125.</p>","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":"13 4","pages":"171-172"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12621859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145497651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gamma Knife Radiosurgery for Advanced and Recurrent Juvenile Nasopharyngeal Angiofibroma: A Case Series.","authors":"Jong Seok Lee, Jung-Il Lee","doi":"10.14791/btrt.2025.0014","DOIUrl":"10.14791/btrt.2025.0014","url":null,"abstract":"<p><p>Juvenile nasopharyngeal angiofibroma (JNA) is a rare, benign, but locally aggressive tumor that typically affects adolescent males. While surgical resection is the standard treatment, achieving total resection is often challenging in advanced-stage tumors with intracranial extension, resulting in high recurrence rates. Gamma knife radiosurgery (GKRS) has been suggested as a potential adjuvant or salvage therapy, but evidence remains limited. In this study, we report three pediatric cases of advanced-stage JNA treated with GKRS following incomplete surgical resection. Two patients demonstrated durable local tumor control with a significant reduction in tumor size until 2 and 12 years after GKRS. The other patient with partial coverage of tumor by prescription isodose 12 Gy showed a reduction of tumor volume at 6 months but subsequent progression at 1 year. No GKRS-related complications were observed during the follow-up period. Our findings suggest that GKRS appears to be a potentially safe and effective treatment modality for residual or recurrent JNAs. Fractionated or staged GKRS combined with surgery may be a preferable strategy for large tumors in which extensive surgery alone, conventional radiotherapy, or single-fraction radiosurgery may be associated with increased morbidity in pediatric populations.</p>","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":"13 3","pages":"106-111"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNA Expression and Neurocognitive Outcomes in Children and Young People With Primary Brain Tumor in Karachi, Pakistan: A Pilot Exploratory Study.","authors":"Nida Zahid, Muhammad Nouman Mughal, Nick Brown, Andreas Mårtensson, Thomas Mårtensson, Muhammad Sufiyan Ibrahim, Sana Naeem, Siraj Qazi, Wajiha Amin, Iqbal Azam, Naureen Mushtaq, Mariya Moochhala, Faiza Kausar, Aneesa Hasan, Farrukh Javeed, Lal Rehman, Sadaf Altaf, Salman Kirmani, Syed Ather Enam","doi":"10.14791/btrt.2025.0006","DOIUrl":"10.14791/btrt.2025.0006","url":null,"abstract":"<p><strong>Background: </strong>microRNAs regulate various cellular pathways and may serve as medium-term prognostic markers in neurocognitive function, as suggested by adult studies. However, no comparable data exist for children with central nervous system tumors. This pilot study explored miRNA expression and its correlation with 12-month posttreatment neurocognitive function in children and young adults (5-21 years) with primary brain tumors.</p><p><strong>Methods: </strong>The study was conducted at Aga Khan University Hospital and Jinnah Postgraduate Medical Center (November 2020 to July 2023). This study analyzed serum levels of miR-21, miR-146a, miR-296-5p, miR-210, and miR-10b using reverse transcriptase quantitative PCR. Neurocognitive assessments using Slosson Intelligence Test, Raven's Progressive Matrices, and Wechsler Intelligence Scale were performed at pretreatment and 12 months posttreatment. The paired t-test was used to assess miRNA expressions, and correlation analysis assessed relationships between pretreatment miRNA expression and neurocognitive outcomes.</p><p><strong>Results: </strong>Of the 48 patients, serum samples were available for analysis from 34 (71%) patients each at pretreatment and 48 hours post-surgery, and 13 (27%) patients at 12 months posttreatment. A statistically significant negative correlation was found between pretreatment miR-210 levels and perceptual reasoning scores at 12 months posttreatment (ρ=-0.59), and a positive correlation between pretreatment miR-10b levels and processing speed scores (ρ=0.49). However, there were no differences in microRNA expressions between pretreatment and 48 hours post-surgery (n=34), pretreatment and 12 months posttreatment (n=13), or 48 hours post-surgery and 12 months posttreatment.</p><p><strong>Conclusion: </strong>This pilot exploratory study found two statistically significant correlations: a negative correlation between pretreatment miR-210 levels and 12 months posttreatment perceptual reasoning scores and a positive correlation between miR-10b expression and 12 months posttreatment speed scores. Further studies are needed to understand the protective or restorative function of miR-10b in cognitive processes and the detrimental role of miR-210 in cognitive processes to evaluate their potential future use as prognostic biomarkers for neurocognitive outcomes in children and young people with primary brain tumors.</p>","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":"13 3","pages":"87-94"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Treatment Outcomes and Prognostic Factors of Intracranial Germ Cell Tumors\".","authors":"Hinpetch Daungsupawong, Viroj Wiwanitkit","doi":"10.14791/btrt.2025.0019","DOIUrl":"10.14791/btrt.2025.0019","url":null,"abstract":"","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":"13 3","pages":"116-117"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Targeting of DNA Damage Response Pathways in <i>TP53</i>- and <i>ATM</i>-Mutated Tumors.","authors":"Ye Jee Shim","doi":"10.14791/btrt.2025.0017","DOIUrl":"10.14791/btrt.2025.0017","url":null,"abstract":"<p><p>Mutations in tumor protein p53 (<i>TP53</i>) and ataxia telangiectasia mutated (<i>ATM</i>) genes are frequently observed across various solid and hematologic malignancies and are associated with genomic instability, treatment resistance, and poor clinical outcomes. These alterations compromise the G1/S cell cycle checkpoint and increase cellular dependence on compensatory DNA damage response (DDR) pathways, including the ataxia telangiectasia and Rad3-related protein kinase (ATR)-checkpoint kinase 1 (CHK1)-WEE1 G2 checkpoint kinase (WEE1) axis. This has led to the development of DDR-targeted therapies that exploit synthetic lethality in tumors with TP53 or ATM dysfunction. Inhibitors targeting ATM, ATR, CHK1, and WEE1 have all shown encouraging activity in early-phase clinical trials, particularly in biomarker-enriched subgroups. Poly(ADP-ribose) polymerase (PARP) inhibitors-originally approved for <i>BRCA1/2</i>-mutated breast cancers-are now being evaluated in <i>TP53</i>- or <i>ATM</i>-deficient tumors, often in combination with other DDR-targeting agents to enhance efficacy. Clinical trials increasingly support the efficacy of DDR inhibitors in biomarker-defined DDR-deficient tumors, specifically beyond <i>BRCA</i> mutations. This review summarizes current understanding of DDR-targeted strategies in <i>TP53</i>- and <i>ATM</i>-mutant cancers, with an emphasis on relevant clinical data and ongoing trials. Expanding the clinical use of DDR inhibitors based on molecular profiles may provide new therapeutic options for genomically unstable tumors across adult and pediatric populations.</p>","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":"13 3","pages":"73-80"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid Resolution of Pulsatile Tinnitus After Gamma Knife Radiosurgery for Tentorial Meningioma Involving the Transverse Sinus.","authors":"Seong-Hyun Park, Min-Seok Woo, Chaejin Lee, Myungsoo Kim, Ki-Su Park, Jeong-Hyun Hwang","doi":"10.14791/btrt.2025.0021","DOIUrl":"10.14791/btrt.2025.0021","url":null,"abstract":"<p><p>Tentorial meningiomas are rare skull base tumors that may cause pulsatile tinnitus when they compress adjacent dural venous sinuses, particularly the transverse sinus. Gamma Knife radiosurgery (GKRS) is an established modality for tumor control, but its role in relieving tinnitus has been infrequently reported. We report a 61-year-old woman with right-sided pulsatile tinnitus caused by a 2-cm tentorial meningioma compressing the right transverse sinus. She underwent GKRS with 13 Gy prescribed to the 50% isodose line, concentrating the 80% isodose volume along the sinus-abutting tumor margin. Her tinnitus resolved completely within one week and remained absent during follow-up. At seven months post-treatment, MRI showed a slight volume decrease (2.81 cm³ to 2.66 cm³), most notable along the sinus interface. The rapid symptom relief despite minimal volumetric change suggests that focused irradiation of sinus-adjacent tumor may alleviate tinnitus by modulating local venous hemodynamics. This case underscores the potential of GKRS to offer early symptomatic improvement in select patients with sinus-involving tentorial meningiomas.</p>","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":"13 3","pages":"112-115"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteogenomic Insights Into Glioblastoma Evolution: Neuronal Reprogramming and Therapeutic Vulnerabilities.","authors":"Harim Koo, Jason K Sa","doi":"10.14791/btrt.2025.0018","DOIUrl":"10.14791/btrt.2025.0018","url":null,"abstract":"<p><p>Glioblastoma (GBM) remains one of the most lethal and treatment-resistant malignancies, characterized by high recurrence rates following standard-of-care therapy. While previous longitudinal studies employing whole-exome and RNA sequencing have revealed patient-specific clonal evolution, they have not identified conserved biological programs that drive recurrence or therapeutic resistance. A recent study published in <i>Cancer Cell</i> presents the first integrated proteogenomic analysis of matched primary and recurrent GBMs. This integrative approach reveals a striking phenotypic transition in recurrent tumors, characterized by neuronal reprogramming supported by coordinated transcriptional, proteomic, and phosphoproteomic evidence. In this review, we contextualize these findings within the broader landscape of GBM evolution, emphasizing the mechanistic contributions of WNT/planar cell polarity (PCP) signaling and BRAF kinase activation in facilitating a neuronal-like state that enhances tumor plasticity, invasion, and treatment resistance. We further discuss how these profound insights align with preclinical models of tumor-neuron synaptic crosstalk, and propose that proteogenomics offers a powerful lens through which to uncover clinically actionable vulnerabilities. By redefining the functional landscape of recurrent GBM, the current study establishes a new framework for biomarker discovery and the rational design of targeted therapies informed by tumor evolution and neuronal niche adaptation.</p>","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":"13 3","pages":"81-86"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Comment on \"Treatment Outcomes and Prognostic Factors of Intracranial Germ Cell Tumors\"-The Author Responds.","authors":"Chae-Yong Kim","doi":"10.14791/btrt.2025.0019re","DOIUrl":"10.14791/btrt.2025.0019re","url":null,"abstract":"","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":"13 3","pages":"118-119"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}